Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
GAITHERSBURG, Md., Oct. 19, 2017 -- Emergent BioSolutions (NYSE:EBS) will release its financial results for the third quarter and nine months of 2017 immediately after market close on Thursday, November 2, 2017. The company will also host a conference call at 5:00 pm (Eastern Time) at which time members of management will discuss these results, as well as recent business developments, revenue and net income guidance for full year 2017 and revenue guidance for fourth quarter 2017.
This conference call can be accessed live by telephone or via webcast:
Live Teleconference Information:
Dial in number: (855) 766-6521
Conference ID: 29706026
Live Webcast Information:
Visit https://edge.media-server.com/m6/p/dvysvtww for the live webcast feed.
A replay of the call can be accessed on Emergent’s website emergentbiosolutions.com under “Investors.”
About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at emergentbiosolutions.com. Follow us @emergentbiosolu.
Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
[email protected]
Media Contact:
Lynn Kieffer
Vice President, Corporate Communications
240-631-3391
[email protected]
